Short answer
Kymera Therapeutics, Inc. (KYMR) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $34M (up 55.5% year over year) with net income of −$69M.
Q1 2026 key financials · XBRL
- Revenue
- $34M
- +55.5% YoY
- Net income
- −$69M
- −5.6% YoY
- Operating margin
- -244.9%
- EPS (diluted)
- −$0.71
- +13.4% YoY
Source: XBRL data from the Kymera Therapeutics, Inc. (KYMR) Q1 2026 10-Q on SEC EDGAR. USD.
Kymera Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $34.4M, up $12.3M from $22.1M YoY
- Net loss $69.2M vs $65.6M YoY; operating loss $84.2M vs $74.4M
- STAT6 highest R&D spend $33.2M, up $12.6M YoY; non-STAT6 activities $25.0M, down $1.4M
- Cash, equivalents and marketable securities $1,546M at March 31, 2026, funding operations into 2029
- Gilead option exercise milestone $45.0M expected as second-quarter 2026 revenue; no product sales expected for several years
Risk Factors
- No newly triggered risk identified; provided section contains no comparison with the prior 10-K
- Liquidity risk: $1,546 million in cash and marketable securities expected to fund operations into 2029
- Clinical-development risk: STAT6 and IRF5 programs remain in early clinical development, while additional programs are preclinical
- Regulatory risk: Clinical holds could delay trial initiation or arise during development as new data emerges
- Financial-services risk: Bank failures could delay access to deposits or cause uninsured losses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kymera Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.